

Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation, 2355 Central Expressway, East Hanover, NJ 07927

Novartis

Clozapine (Clozaril) Tablets

Section	Text
Indication	For the treatment of schizophrenia in patients who have not responded adequately to one or more antipsychotic medications.
Warnings	Myocarditis and cardiomyopathy. Clozapine (CPK) levels should be monitored. Clozapine should be discontinued if myocarditis or cardiomyopathy is suspected.
Contraindications	Concomitant use with other serotonergic agents. Clozapine should not be used in patients with a known hypersensitivity to clozapine or any of its components.
Precautions	Neutropenia and agranulocytosis. Clozapine should be discontinued if the absolute neutrophil count (ANC) falls below 1500/mm ³ .
Adverse Reactions	Common adverse reactions include drowsiness, dry mouth, constipation, and weight gain.
Drug Interactions	Clozapine may interact with other medications, including antidepressants and blood thinners.
Use in Specific Populations	Use in elderly patients, pregnant women, and nursing mothers should be carefully monitored.

For more information, visit www.novartis.com

Novartis Pharmaceuticals Corporation, 2355 Central Expressway, East Hanover, NJ 07927

Novartis

<mailto:clozaril.remote@novartis.com>

Call 1-800-222-8814 for more information

Call 1-800-900-1730 for more information

Novartis

Call 1-800-012-003-293 for more information

Call 1-800-900-1730 for more information

www.novartis.com

Source URL: <https://www.pro.novartis.com/jp-ja/products/clozaril/clinical/13>